Effects of ropinirole on nonmotor symptoms of parkinson disease: A prospective multicenter study

Clinical Neuropharmacology

Volumn 31, Issue 5, 2008, Pages 261-266

  Rektorova, Irena ^a   Balaz, Marek ^a   Svatova, Jindra ^b   Zarubova, Katerina ^c   Honig, Igor ^d   Dostal, Vaclav ^e   Sedlackova, Silvie ^a   Nestrasil, Igor ^a   Mastik, Jiri ^a   Bares, Martin ^a   Veliskova, Jana ^f   Dusek, Ladislav ^g  

^a ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^d Bata Hospital   (Czech Republic)

^e Hospital Pardubice   (Czech Republic)

^f PALACKÝ UNIVERSITY   (Czech Republic)

^g MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Anxiety; Depressive; Parkinson's disease; Ropinirole; Sleep

Indexed keywords

LEVODOPA; ROPINIROLE; SEX HORMONE; TESTOSTERONE; INDOLE DERIVATIVE;

ADULT; AGED; ANXIETY; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DAYTIME SOMNOLENCE; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DYSKINESIA; EPWORTH SLEEP SCALE; FEMALE; FEMALE SEXUAL FUNCTION INDEX; HAMILTON ANXIETY SCALE; HORMONE BLOOD LEVEL; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; NIGHTMARE; PARKINSON DISEASE; PARKINSON DISEASE SLEEP SCALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; SCORING SYSTEM; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SLEEP; SLEEP DISORDER; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE; BEHAVIOR; COMPARATIVE STUDY; FOLLOW UP; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; TREMOR;

AGED; ANXIETY; BEHAVIORAL SYMPTOMS; DEPRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; MALE; MIDDLE AGED; PARKINSON DISEASE; PROSPECTIVE STUDIES; SLEEP DISORDERS; TREMOR;

EID: 65849303078     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31815d25ce     Document Type: Article

References (31)

1. Goetz CG, Poewe W, Rascol O, et al. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005;20:523-539.
2. Chaudhuri KR, Healy DG, Schapira AHV. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006;5:235-245.
3. Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003; 10:1-8.
4. Lemke MR, Brecht HM, Koester J, et al. Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci 2005;17:214-220.
5. Barone P, Scarzella L, Marconi R, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease. A national multicenter parallel-group randomized study. J Neurol 2006; 253:555-561.
6. Corrigan MH, Denahan AQ, Wright CE, et al. Comparison of pramipexol, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000;11:58-65.
7. Rogers DC, Costall B, Domeney PA, et al. Anxiolytic profile of ropinirole in the rat, mouse and common marmoset. Psychopharmacology 2000;151:91-97.
8. Cassano P, Lattanzi L, Fava M, et al. Ropinirole in treatment-resistant depression: a 16-week pilot study. Can J Psychiatry 2005;50:357-360.
9. Perugi G, Toni C, Ruffolo G, et al. Adjunctive dopamine agonist in treatment-resistant bipolar II depression: an open case series. Pharmacopsychiatry 2001;34:137-141.
10. Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomised, controlled study in advanced Parkinson's disease. Neurology 2007;68:1108-1115.
11. Buchwald B, Angersbach D, Jost WH. Improvements in motor and non-motor symptoms in Parkinson patients under ropinirole therapy [in German]. Fortschr Neurol Psychiatr 2007;4:236-241.
12. Melis MR, Argiolas A. Dopamine and sexual behavior. Neurosci Biobehav Rev 1995;19: 635-641.
13. Kanovsky P, Bares M, Pohanka M, et al. Penile erections and hypersexuality induced by pergolide treatment in advanced, fluctuating Parkinson's disease. J Neurol 2002;249:112-114.
14. Worthington JJ, Simon NM, Korbly NB, et al. Ropinirole for antidepressant-induced sexual dysfunction. Int Clin Psychopharmacol 2002;17: 307-310.
15. Frucht R, Rogers JD, Greene PE, et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999; 52:1908-1910.
16. Folstein M, Folstein S, McHughs P. The 'Mini Mental State': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
17. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
18. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55.
19. Montgomery SA, Asberg MA. A new depression scale designed to be sensitive to change. Br J Psychiatry 1975;134:382-389.
20. Chaudhuri KR, Pal S, DiMarco A, et al. The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002;73:629-635.
21. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540-545.
22. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-830.
23. Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26: 191-208.
24. Fahn S, Elston RL, and members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, et al., eds. Recent Developments in Parkinson's Disease Vol 2. New York: MacMillan; 1987:153-163.
25. Lieberman A. Depression in Parkinson's disease - a review. Acta Neurol Scand 2006;113:1-8.
26. Maricle RA, Nutt JG, Valentine RJ, et al. Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo-controlled study. Neurology 1995;45:1757-1760.
27. Marsh L, McDonald WM, Cummings J, et al. Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIHM work group. Mov Disord 2006;21:148-158.
28. Chaudhuri KR, Martinez-Martin P. Clinical assessment of nocturnal disability in Parkinson's disease: the Parkinson's Disease Sleep Scale. Neurology 2004;63(Suppl3):S17-S20.
29. McNamara P, Hartus E, Szent-Imrey R, et al. Relation of mood and cognitive deficits to sleep disturbance in patients with Parkinson's disease. P08.084. Presented at: 59th AAN Annual Meeting; 2007; Boston, MA.
30. Aikey JL, Nyby JG, Anmuth DM, et al. Testosterone rapidly reduces anxiety in male house mice (Mus musculus). Horm Behav 2002;42:448-460.
31. Okun MS, Fernandez HH, Rodriguez RL, et al. Testosterone therapy in men with Parkinson's disease. Results of the TEST-PD study. Arch Neurol 2006;63:729-735.